Layton, Thomas B.
Williams, Lynn
McCann, Fiona http://orcid.org/0000-0001-8151-8781
Zhang, Mingjun http://orcid.org/0000-0002-0641-1877
Fritzsche, Marco
Colin-York, Huw
Cabrita, Marisa
Ng, Michael T. H. http://orcid.org/0000-0003-3463-5568
Feldmann, Marc
Sansom, Stephen N. http://orcid.org/0000-0003-4569-8513
Furniss, Dominic http://orcid.org/0000-0003-2780-7173
Xie, Weilin
Nanchahal, Jagdeep http://orcid.org/0000-0002-9579-9411
Funding for this research was provided by:
Celgene (AZR00610)
Article History
Received: 17 December 2019
Accepted: 20 April 2020
First Online: 2 June 2020
Change Date: 24 June 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: J.N. and M. Feldmann declare that they are co-founders and have equity in 180 Therapeutics, which has exclusively licensed IP from the University of Oxford for the treatment of Dupuytren’s disease. The remaining authors declare no competing interests.